Clinical trials: Skin Absorption
- Condition Skin Absorption
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Psoriasis
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque…
- Trial name
- NCT03988439
- Testing
- IDP-118 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 16 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants…
- Trial name
- NCT03987763
- Testing
- IDP-122 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 45 people
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e.
- Trial name
- NCT00925730
- Testing
- Pimecrolimus
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis
Acne
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris
Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion.
- Trial name
- NCT02849860
- Testing
- IDP-121 Lotion
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bausch Health Americas, Inc.
Acne
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac Cream.
- Trial name
- NCT02849873
- Testing
- IDP-123 Lotion, Tazorac Cream
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Onychomycosis
A Study of the Systemic Absorption of MOB015B
A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
- Trial name
- NCT03244280
- Testing
- MOB015B
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moberg Pharma AB
Acne
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.
- Trial name
- NCT02850003
- Testing
- IDP-120 Gel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel
This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.
- Trial name
- NCT03653403
- Testing
- IDP-126 Gel, Control Gel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Bausch Health Americas, Inc.